110 related articles for article (PubMed ID: 20038760)
1. The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
Racke MK; Lovett-Racke AE; Karandikar NJ
Neurology; 2010 Jan; 74 Suppl 1():S25-30. PubMed ID: 20038760
[TBL] [Abstract][Full Text] [Related]
2. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.
Weiner HL
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3333-5. PubMed ID: 10097037
[No Abstract] [Full Text] [Related]
3. Immunology of multiple sclerosis.
McFarland HF
Ann N Y Acad Sci; 1988; 540(1):99-105. PubMed ID: 2974693
[No Abstract] [Full Text] [Related]
4. Sites of antigen presentation in T-cell mediated demyelinating diseases.
Massa PT
Res Immunol; 1989 Feb; 140(2):196-201; discussion 245-8. PubMed ID: 2662284
[No Abstract] [Full Text] [Related]
5. Polypeptide agonists of innate immune sensors.
Dion MZ; Artzi N
Nat Biomed Eng; 2024 May; 8(5):495-496. PubMed ID: 38778182
[No Abstract] [Full Text] [Related]
6. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
Hecker M; Thamilarasan M; Koczan D; Schröder I; Flechtner K; Freiesleben S; Füllen G; Thiesen HJ; Zettl UK
Int J Mol Sci; 2013 Aug; 14(8):16087-110. PubMed ID: 23921681
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
Aharoni R
Autoimmun Rev; 2013 Mar; 12(5):543-53. PubMed ID: 23051633
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of action of interferon-β in relapsing multiple sclerosis.
Kieseier BC
CNS Drugs; 2011 Jun; 25(6):491-502. PubMed ID: 21649449
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
10. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China.
Guo J; Wu J; Wang L; Liu H; Wu X; Yang H; Li W; Wang H; Bu B; Yang C; Zhou H; Guo S; Zhao Y; Wang Z; Li C; Tian DC; Chen S; Xue H; Zhang Y; Xu Y; Liang H; Wu Z; Zhang Y; Dong Q; Wang J; Quan C
Ther Adv Neurol Disord; 2024; 17():17562864241239117. PubMed ID: 38616782
[TBL] [Abstract][Full Text] [Related]
11. Protective Effects of Glatiramer Acetate Against Paclitaxel-Induced Peripheral Neuropathy in Rats: A Role for Inflammatory Cytokines and Oxidative Stress.
Dekamin S; Ghasemi M; Dehpour AR; Ghazi-Khansari M; Shafaroodi H
Neurochem Res; 2024 Apr; 49(4):1049-1060. PubMed ID: 38252396
[TBL] [Abstract][Full Text] [Related]
12. Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.
Rastkar M; Ghajarzadeh M; Sahraian MA
Curr J Neurol; 2023 Apr; 22(2):115-136. PubMed ID: 38011449
[No Abstract] [Full Text] [Related]
13. N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial.
Sy M; Newton BL; Pawling J; Hayama KL; Cordon A; Yu Z; Kuhle J; Dennis JW; Brandt AU; Demetriou M
J Neuroinflammation; 2023 Sep; 20(1):209. PubMed ID: 37705084
[TBL] [Abstract][Full Text] [Related]
14. Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis.
Liu C; Zhu J; Mi Y; Jin T
J Neuroinflammation; 2022 Dec; 19(1):298. PubMed ID: 36510261
[TBL] [Abstract][Full Text] [Related]
15. microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate.
Dominguez-Mozo MI; Casanova I; De Torres L; Aladro-Benito Y; Perez-Perez S; Garcia-Martínez A; Gomez P; Abellan S; De Antonio E; Lopez-De-Silanes C; Alvarez-Lafuente R
Front Immunol; 2022; 13():904683. PubMed ID: 35774792
[TBL] [Abstract][Full Text] [Related]
16. A moisture-tolerant route to unprotected α/β-amino acid N-carboxyanhydrides and facile synthesis of hyperbranched polypeptides.
Tian ZY; Zhang Z; Wang S; Lu H
Nat Commun; 2021 Oct; 12(1):5810. PubMed ID: 34608139
[TBL] [Abstract][Full Text] [Related]
17. The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
Melnikov M; Sharanova S; Sviridova A; Rogovskii V; Murugina N; Nikolaeva A; Dagil Y; Murugin V; Ospelnikova T; Boyko A; Pashenkov M
PLoS One; 2020; 15(10):e0240305. PubMed ID: 33126239
[TBL] [Abstract][Full Text] [Related]
18. Microglial Phagocytosis-Rational but Challenging Therapeutic Target in Multiple Sclerosis.
Pinto MV; Fernandes A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825077
[TBL] [Abstract][Full Text] [Related]
19. Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
Vasileiadis GK; Dardiotis E; Mavropoulos A; Tsouris Z; Tsimourtou V; Bogdanos DP; Sakkas LI; Hadjigeorgiou GM
Auto Immun Highlights; 2018 Nov; 9(1):9. PubMed ID: 30415321
[TBL] [Abstract][Full Text] [Related]
20. S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis.
Saxena N; Won J; Choi S; Singh AK; Singh I
Free Radic Biol Med; 2018 Jun; 121():57-68. PubMed ID: 29694854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
